Genmab — Marts 2017
-
Var det ikke et oplagt studie for Gen at sponsorere selv? Givet at man potentielt kan få dara ud i en ekstra indikation samt løfte salget af Arzerra. Jeg læser et fase 3 studie koster ~1 mio per patient. Mon ikke risk/reward scenariet ser ganske fornuftigt ud ved at betale 500 mio for sådan et studie? Ville elske at den store kassebeholdning blev brugt på sådan et skud. Men hvad ved jeg
-
Og hvad er mon forklaringen på at man endnu ikke er i klinik med Dara i pågældende kræftform? http://www.onclive.com/web-exclusives/daratumumab
-produces-dramatic-responses-in-relapsed-light-chain-amyloidosis -
-
-
@stockBull: from Saxo Bank who has sent notifications to account holders with positions that will be affected by the changes.. I although know customers with open positions that didn't yet get any email.. So, if you doubt, then contact Saxo Bank..
-
Lars Tvede skal man ikke kimse af http://borsen.dk/nyheder/avisen/artikel/11/164918/artikel.html
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind